Stock IVVD INVIVYD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
1.21 USD -4.72% Intraday chart for Invivyd, Inc. -13.57% -69.29%
06-14 Invivyd Announces Antiviral Activity of VYD222 Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants CI
05-31 Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
GL
Invivyd to Participate at the Jefferies Global Healthcare Conference
GL
INVIVYD ANNOUNCES GENERAL ALIGNMENT WITH U.S. FDA ON A REPEATABLE, EXPEDIENT EMERGENCY USE AUTHORIZATION PATHWAY FOR THE PREVENTION AND TREATMENT OF SYMPTOMATIC COVID-19, BASED ON COMPACT CLINICAL PROGRAMS
AQ
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
GL
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
GL
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
GL
Invivyd Elects Two New Independent Members to its Board of Directors
GL
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Invivyd : Q1 2024 Invivyd Earnings Conference Call
PU
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
AQ
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
GL
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO
AQ
INVIVYD ANNOUNCES CEO TRANSITION
AQ
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
GL
Invivyd Announces CEO Transition
GL
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
GL
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVVD Stock
  4. News Invivyd, Inc.
  5. Press Releases